DrugBiological
Zalutumumab clinical trials
Also written HuMax-EGFr.
- studies test it
- 10
- open now
- 0
- in phase 3
- 2
- first study started
- 2003
How studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
9 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 3 |
| 2010 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 8
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 1
Studies
Open first, then newest update. How each study uses zalutumumab is read from its arms, and is right about nine times in ten.
Testing it · 10
- Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)CompletedPhase 1/2GenmabNCT01054625Written as zalutumumab
- Zalutumumab in Non-curable Patients With SCCHNCompletedPhase 2GenmabNCT00542308Written as Zalutumumab
- Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based ChemotherapyTerminatedPhase 1/2GenmabNCT00707655Written as Zalutumumab
- Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal CancerTerminatedPhase 1/2GenmabNCT00677924Written as Zalutumumab
- Zalutumumab in Head and Neck CancerCompletedPhase 1/2GenmabNCT00093041Written as Zalutumumab
- DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCCCompletedPhase 3Danish Head and Neck Cancer GroupNCT00496652Written as Zalutumumab
- Zalutumumab in Patients With Non-curable Head and Neck CancerCompletedPhase 3GenmabNCT00382031Written as Zalutumumab
- Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck CancerTerminatedPhase 1/2GenmabNCT00401401Written as zalutumumab
- Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung CancerTerminatedPhase 2GenmabNCT00460551Written as Zalutumumab
- Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase InhibitorsWithdrawnPhase 2GenmabNCT01449357Written as zalutumumab
Codes
What other systems call zalutumumab · ClinicalTrials.gg INT005562
- MeSH (NLM) C546618zalutumumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) DA709Q5020ZALUTUMUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q8065569ZalutumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C64620ZalutumumabOne source FDA
- DrugBank DB12202One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C546618 | zalutumumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | DA709Q5020 | ZALUTUMUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q8065569 | Zalutumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C64620 | Zalutumumab | One source FDA |
| DrugBank | DB12202 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.